{"doi":"10.1038/s41598-022-21175-7","title":"Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>Strong prognostic biomarkers are lacking regarding the stratification of treatment and surveillance regimens in head and neck squamous cell carcinoma (HNSCC). The study aimed to assess the prognostic value of soluble urokinase-type plasminogen activator receptor in plasma (suPAR) compared to evaluation by uPAR-positron-emission-tomography (PET) in HNSCC patients. Plasma from 19 controls and 49 HNSCC patients referred to curatively intended radiotherapy (2017–2021) was collected pre-treatment and post-treatment (n = 37). Information on uPAR-PET was available from previous evaluation. Patient median suPAR was significantly higher pre- and post-treatment compared to controls (p = 0.013, p = 0.003) and increased significantly during radiotherapy (p = 0.003). Pre-treatment suPAR did not predict survival outcomes. Post-treatment suPAR significantly predicted RFS (HR = 6.67 (95% CI 1.44–30.9) p = 0.015), but not OS (HR = 3.29 (95% CI 0.882–12.3) p = 0.076) in univariate analysis. RFS prediction was maintained for post-treatment suPAR in multivariate analysis, including TNM-stage (HR = 6.62 (95% CI 1.40–31.4) p = 0.017). Pre-treatment uPAR-PET/CT and post-treatment suPAR was available in 24 patients. High uPAR-estimates on both modalities was significantly associated with poor RFS compared to patients with low uPAR-estimates (log-rank, p = 0.008). Patients with discordant uPAR-estimates (one-low/one-high) were at intermediate risk, although non-significant (p = 0.131). In conclusion, pre-treatment suPAR did not predict RFS or OS. Pre-treatment uPAR-PET and post-treatment suPAR predicted RFS.</jats:p>","journal":"Scientific Reports","year":2022,"id":592987,"datarank":0.35776772750954355,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.08900380712533526,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.08900380712533526,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":4,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1517561,"name":"Tina Binderup","orcid":null,"position":1,"is_corresponding":false},{"id":1517562,"name":"Marie Øbro Fosbøl","orcid":null,"position":2,"is_corresponding":false},{"id":1517563,"name":"Kim Francis Andersen","orcid":null,"position":3,"is_corresponding":false},{"id":44500,"name":"Annika Loft","orcid":null,"position":4,"is_corresponding":false},{"id":587150,"name":"Jeppe Friborg","orcid":"0000-0001-5423-0627","position":5,"is_corresponding":false},{"id":166419,"name":"Andreas Kjaer","orcid":null,"position":6,"is_corresponding":false},{"id":1517560,"name":"Louise Madeleine Risør","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:p>Strong prognostic biomarkers are lacking regarding the stratification of treatment and surveillance regimens in head and neck squamous cell carcinoma (HNSCC). The study aimed to assess the prognostic value of soluble urokinase-type plasminogen activator receptor in plasma (suPAR) compared to evaluation by uPAR-positron-emission-tomography (PET) in HNSCC patients. Plasma from 19 controls and 49 HNSCC patients referred to curatively intended radiotherapy (2017–2021) was collected pre-treatment and post-treatment (n = 37). Information on uPAR-PET was available from previous evaluation. Patient median suPAR was significantly higher pre- and post-treatment compared to controls (p = 0.013, p = 0.003) and increased significantly during radiotherapy (p = 0.003). Pre-treatment suPAR did not predict survival outcomes. Post-treatment suPAR significantly predicted RFS (HR = 6.67 (95% CI 1.44–30.9) p = 0.015), but not OS (HR = 3.29 (95% CI 0.882–12.3) p = 0.076) in univariate analysis. RFS prediction was maintained for post-treatment suPAR in multivariate analysis, including TNM-stage (HR = 6.62 (95% CI 1.40–31.4) p = 0.017). Pre-treatment uPAR-PET/CT and post-treatment suPAR was available in 24 patients. High uPAR-estimates on both modalities was significantly associated with poor RFS compared to patients with low uPAR-estimates (log-rank, p = 0.008). Patients with discordant uPAR-estimates (one-low/one-high) were at intermediate risk, although non-significant (p = 0.131). In conclusion, pre-treatment suPAR did not predict RFS or OS. Pre-treatment uPAR-PET and post-treatment suPAR predicted RFS.</jats:p>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36352036","pmcid":"PMC9645757","openalex_id":"https://openalex.org/W4308627599","authors":[],"funders":[{"funder_name":"Lundbeck Foundation","grant_id":"R310-2019-167","title":null},{"funder_name":"Lundbeck Foundation","grant_id":"R278-2018-548","title":null},{"funder_name":"European Research Council","grant_id":"668532","title":"“In Vivo Click PET Imaging Agents”: Improving clinical companion diagnostics"},{"funder_name":"Novo Nordisk Fonden","grant_id":"NNF20OC0062819","title":null},{"funder_name":"European Commission","grant_id":"670261","title":"Molecular imaging and targeted therapy of the aggressive phenotype: development of uPAR theranostics for cancer patients"}],"total_grants":5,"fwci":0.922,"citation_percentile":0.74296658,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.nature.com/articles/s41598-022-21175-7.pdf","host_type":"journal"},{"url":"https://www.nature.com/articles/s41598-022-21175-7.pdf","host_type":"publisher"},{"url":"https://www.nature.com/articles/s41598-022-21175-7","host_type":"publisher"},{"url":"https://doi.org/10.1038/s41598-022-21175-7","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36352036","host_type":"repository"},{"url":"https://doaj.org/article/35e82c4c3445423784ed6b617e4aeb15","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9645757","host_type":"repository"},{"url":"https://researchprofiles.ku.dk/da/publications/c7b370f4-533b-425c-9dfb-cdacb7b11f71","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9645757","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9645757?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1038/s41598-022-21175-7","host_type":""},{"url":"http://www.scopus.com/inward/record.url?scp=85141458601&partnerID=8YFLogxK","host_type":""},{"url":"https://curis.ku.dk/ws/files/327055703/Urokinase_type_plasminogen.pdf","host_type":""},{"url":"https://doi.org/https://doi.org/10.1038/s41598-022-21175-7","host_type":""}],"fields_of_study":["Head and Neck Cancer Studies","Protease and Inhibitor Mechanisms","Peptidase Inhibition and Analysis","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["Positron Emission Tomography Computed Tomography","Liquid Biopsy","Squamous Cell Carcinoma of Head and Neck","Head and Neck Neoplasms","Humans","Tomography, X-Ray Computed","Urokinase-Type Plasminogen Activator","Receptors, Urokinase Plasminogen Activator"],"keywords":["Urokinase receptor","Plasminogen activator","Head and neck cancer","Medicine","Head and neck","Urokinase","Receptor","Cancer","Cancer research","Pathology","Internal medicine","Oncology","Surgery","Squamous Cell Carcinoma of Head and Neck","Science","Q","R","Liquid Biopsy","Urokinase-Type Plasminogen Activator","Article","Receptors, Urokinase Plasminogen Activator","Head and Neck Neoplasms","Positron Emission Tomography Computed Tomography","Humans","Tomography, X-Ray Computed"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T16:33:30.857580Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}